Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

In a statement today, the company said it supports recent precautionary measures and that thorough investigations are needed ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Centres for Disease Control and Prevention (CDC) has issued an advisory urging American travellers over the age of 60 years ...

Valneva is committed to upholding the highest safety standards and has engaged proactively with health authorities in all territories where IXCHIQ ® is licensed to provide timely information about all ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...